相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study
Devalingam Mahalingam et al.
CLINICAL CANCER RESEARCH (2020)
Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study
Suneel D. Kamath et al.
ONCOLOGIST (2020)
Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic
Takahiro Tsujikawa et al.
CLINICAL CANCER RESEARCH (2020)
Targeting Myeloid-Derived Suppressor Cells in Cancer Immunotherapy
Yufei Wang et al.
CANCERS (2020)
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study
Mark H O'Hara et al.
LANCET ONCOLOGY (2020)
Is Screening for Pancreatic Cancer in High-Risk Individuals One Step Closer or a Fool's Errand?
Phil A. Hart et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Molecular subtypes of pancreatic cancer
Eric A. Collisson et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)
Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review
Ritu R. Singh et al.
CANCER TREATMENT REVIEWS (2019)
Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)
Dung T. Le et al.
CLINICAL CANCER RESEARCH (2019)
Finding Room for Success
Margaret Tempero
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Advances in cancer immunotherapy 2019-latest trends
Stephan Kruger et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Talia Golan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial
Eileen M. O'Reilly et al.
JAMA ONCOLOGY (2019)
Strategies in Developing Immunotherapy for Pancreatic Cancer: Recognizing and Correcting Multiple Immune Defects in the Tumor Microenvironment
Sireesha Upadhrasta et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
J. Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Pancreatic cancer microenvironment: a current dilemma
Burak Uzunparmak et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2019)
An update on treatment options for pancreatic adenocarcinoma
Aurelien Lambert et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
Genomics meets immunity in pancreatic cancer: Current research and future directions for pancreatic adenocarcinoma immunotherapy
Jacob S. Bowers et al.
ONCOLOGY REVIEWS (2019)
Pancreatic cancer incidence trends: evidence from the Surveillance, Epidemiology and End Results (SEER) population-based data
Vanessa L. Gordon-Dseagu et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2018)
Emerging trends in the immunotherapy of pancreatic cancer
Kasturi Banerjee et al.
CANCER LETTERS (2018)
Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial
Gregory L. Beatty et al.
GASTROENTEROLOGY (2018)
Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study
Margaret K. Callahan et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Connective tissue growth factor-specific monoclonal antibody inhibits growth of malignant mesothelioma in an orthotopic mouse model
Yuuki Ohara et al.
Oncotarget (2018)
Talimogene laherparepvec: First in class oncolytic virotherapy
Robert M. Conry et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2018)
Immunotherapy and Combination Strategies in Pancreatic Cancer: Current Status and Emerging Trends
Phyllis F. Cheung et al.
ONCOLOGY RESEARCH AND TREATMENT (2018)
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
Michael M. Boyiadzis et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma
Devalingam Mahalingam et al.
CANCERS (2018)
Tumor microenvironment participates in metastasis of pancreatic cancer
Bo Ren et al.
MOLECULAR CANCER (2018)
Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options
Derya Kabacaoglu et al.
FRONTIERS IN IMMUNOLOGY (2018)
Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features
Francesco Puleo et al.
GASTROENTEROLOGY (2018)
Immunotherapy in pancreatic adenocarcinoma-overcoming barriers to response
Ari Rosenberg et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2018)
Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward
Mohammad Aslam Khan et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels
James N. Kochenderfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Vaccination with poly (IC: LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer
Shikhar Mehrotra et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Overcoming the resistance of pancreatic cancer to immune checkpoint inhibitors
Richard A. Skelton et al.
JOURNAL OF SURGICAL ONCOLOGY (2017)
Review: Oncolytic virotherapy, updates and future directions
Christos Fountzilas et al.
ONCOTARGET (2017)
Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer Immunotherapy
Xingchun Gao et al.
FRONTIERS IN IMMUNOLOGY (2017)
Genomic analyses identify molecular subtypes of pancreatic cancer
Peter Bailey et al.
NATURE (2016)
Targeting tumor-associated macrophages to combat pancreatic cancer
Ran Cui et al.
ONCOTARGET (2016)
Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors
MacLean Hall et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Immune Checkpoint Inhibitors for Cancer Therapy: Clinical Efficacy and Safety
Said C. Azoury et al.
CURRENT CANCER DRUG TARGETS (2015)
Whole genomes redefine the mutational landscape of pancreatic cancer
Nicola Waddell et al.
NATURE (2015)
Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma
Richard A. Moffitt et al.
NATURE GENETICS (2015)
A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma
Gregory L. Beatty et al.
CLINICAL CANCER RESEARCH (2013)
Inflammatory networks and immune surveillance of pancreatic carcinoma
Robert H. Vonderheide et al.
CURRENT OPINION IN IMMUNOLOGY (2013)
Addition of Algenpantucel-L Immunotherapy to Standard Adjuvant Therapy for Pancreatic Cancer: a Phase 2 Study
Jeffrey M. Hardacre et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2013)
Immune infiltrates as predictive markers of survival in pancreatic cancer patients
Maria Pia Protti et al.
FRONTIERS IN PHYSIOLOGY (2013)
Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors
Giulia Mesiano et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2012)
Targeting Mutated K-ras in Pancreatic Adenocarcinoma Using an Adjuvant Vaccine
Ghassan K. Abou-Alfa et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2011)
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Gregory L. Beatty et al.
SCIENCE (2011)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer
Chigusa Morizane et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study
S. L. Bernhardt et al.
BRITISH JOURNAL OF CANCER (2006)
Cytokine-induced killer T cells kill immature dendritic cells by TCR-independent and perforin-dependent mechanisms
Pramod S. Joshi et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2006)
Genetically induced pancreatic adenocarcinoma is highly immunogenic and causes spontaneous tumor-specific immune responses
AI Garbe et al.
CANCER RESEARCH (2006)
The immunobiology of cancer immunosurveillance and immunoediting
GP Dunn et al.
IMMUNITY (2004)
Targeting tumours with genetically enhanced T lymphocytes
M Sadelain et al.
NATURE REVIEWS CANCER (2003)
分享论文
